Exonics is a new gene editing company focused on developing a cure for Duchenne muscular dystrophy. The company is based on the ground-breaking work of its founder, Dr. Eric Olson, and will utilize CRISPR/Cas9 to treat muscle diseases.
Research focus: Gene editing/CRISPR
Funding Need: $2,500,000 – CureDuchenne is providing matching funds to Exonics Therapeutics for a total of $5M in pre-clinical research funding
“The creation of Exonics, in conjunction with CureDuchenne Ventures, will allow us to work toward a one-time therapy that would make a big impact on the lives of Duchenne patients. CureDuchenne has strong relationships with the Duchenne community including patients, families, physicians and scientists in academia and industry. These relationships, CureDuchenne’s deep knowledge of Duchenne and all the therapeutic approaches for the disease; and their strong leadership team make them a great partner to help accelerate drug development.” – Dr. Olson, scientific founder and chief science advisor, Exonics Therapeutics who also serves as Professor and Chairman of the Department of Molecular Biology at the University of Texas Southwestern Medical Center, from which Exonics’ technology is licensed.